ArticleCurrent microbiology2026
Antimicrobial and Antitumor Activities of Endophytic Fungi from the Medicinal Plant Paris polyphylla var. yunnanensis.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Endophytic fungi, due to their unique ecological niche and long-term coevolution with host plants, can produce structurally diverse secondary metabolites with various biological activities, providing abundant resources for the development of new drugs. This study focuses on 17 strains of endophytic fungi belonging to 16 genera isolated from a rare Chinese herbal medicine of Paris polyphylla var. yunnanensis, with a particular emphasis on their antimicrobial activity against Staphylococcus aureus and Escherichia coli, and antitumor activity against six human cancer cell lines (HepG2, 143B, HT-29, A375, A549, SKOV-3). All 17 strains exhibited certain antibacterial and antitumour activity. Significantly, two strains were shown to have remarkable dual activity. X2-2 (Penicillium oxalicum) and X8-4 (Chaetomium nozdrenkoae) demonstrated significant antimicrobial activity against S. aureus with MIC values 1.95 and 3.9 µg/mL determined by broth microdilution assay. The CCK8 assay showed that these two strains also exhibited broad-spectrum antitumor activity, with IC50 values < 10 µg/mL against all six cancer cell lines. X2-2 showed superior antitumor activity against 143B cells (IC50 = 2.49 ± 0.77 µg/mL), while X8-4 exhibited high potency against HepG2 cells (IC50 = 1.53 ± 0.71 µg/mL), with superiority over Doxorubicin and hydroxycamptothecin, respectively. GC-MS analysis identified 24 and 30 compounds in the crude extracts of X2-2 and X8-4, respectively, and the major compounds may play a dominant role in their biological activity. Collectively, the present study revealed that X2-2 and X8-4 are prospective sources of antimicrobial and antitumor drugs, which lays a theoretical foundation for the application of endophytic fungal resources from P. polyphylla var. yunnanensis.
Indexed as
Identifiers
42029943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.